Identifying the Need for Good Practices in Health Technology Assessment : Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA

Published on Jan 1, 2019in Value in Health5.037
· DOI :10.1016/j.jval.2018.08.010
Finn Børlum Kristensen12
Estimated H-index: 12
(University of Southern Denmark),
Don Husereau20
Estimated H-index: 20
(U of O: University of Ottawa)
+ 14 AuthorsAllan Wailoo30
Estimated H-index: 30
(University of Sheffield)
The systematic use of evidence to inform healthcare decisions, particularly health technology assessment (HTA), has gained increased recognition. HTA has become a standard policy tool for informing decision makers who must manage the entry and use of pharmaceuticals, medical devices, and other technologies (including complex interventions) within health systems, for example, through reimbursement and pricing. Despite increasing attention to HTA activities, there has been no attempt to comprehensively synthesize good practices or emerging good practices to support populationbased decision-making in recent years. After the identification of some good practices through the release of the ISPOR Guidelines Index in 2013, the ISPOR HTA Council identified a need to more thoroughly review existing guidance. The purpose of this effort was to create a basis for capacity building, education, and improved consistency in approaches to HTA-informed decision-making. Our findings suggest that although many good practices have been developed in areas of assessment and some other key aspects of defining HTA processes, there are also many areas where good practices are lacking. This includes good practices in defining the organizational aspects of HTA, the use of deliberative processes, and measuring the impact of HTA. The extent to which these good practices are used and applied by HTA bodies is beyond the scope of this report, but may be of interest to future researchers.
  • References (113)
  • Citations (5)
📖 Papers frequently viewed together
39 Citations
7 Authors (Jipan Xie, ..., Cinzia Metallo)
1 Citations
4 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Louis P. Garrison (UW: University of Washington)H-Index: 29
#2Peter J. Neumann (Tufts Medical Center)H-Index: 81
Last. Milton C. Weinstein (Harvard University)H-Index: 111
view all 13 authors...
Abstract This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health economics approach to the question of whether a health plan should cover and reimburse a specific technology, beginning with the view that the conventional cost-per-quality-adjusted life-year metric has both strengths as a starting point and recognized limitations. This report calls for the development of a more compr...
29 CitationsSource
#1Romina Brignardello-Petersen (University of Chile)H-Index: 23
#2Ashley Bonner (McMaster University)H-Index: 13
Last. Gordon H. Guyatt (McMaster University)H-Index: 201
view all 13 authors...
Abstract This article describes conceptual advances of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group guidance to evaluate the certainty of evidence (confidence in evidence, quality of evidence) from network meta-analysis (NMA). Application of the original GRADE guidance, published in 2014, in a number of NMAs has resulted in advances that strengthen its conceptual basis and make the process more efficient. This guidance will be useful for systematic...
42 CitationsSource
#3Helga SigmundH-Index: 6
Health Technology Assessment Handbook , Health Technology Assessment Handbook , کتابخانه مرکزی دانشگاه علوم پزشکی ایران
10 Citations
#1Wija Oortwijn (Ecorys)H-Index: 11
#2Domino Determann (Ecorys)H-Index: 1
Last. Jeroen van der Tuin (Ecorys)H-Index: 2
view all 5 authors...
Abstract Objectives To assess the level of comprehensiveness of health technology assessment (HTA) practices around the globe and to formulate recommendations for enhancing legitimacy and fairness of related decision-making processes. Methods To identify best practices, we developed an evaluation framework consisting of 13 criteria on the basis of the INTEGRATE-HTA model (integrative perspective on assessing health technologies) and the Accountability for Reasonableness framework (deliberative a...
8 CitationsSource
#1Nicola Allen (Cardiff University)H-Index: 4
#2Lawrence LibertiH-Index: 7
Last. Sam Salek (Cardiff University)H-Index: 17
view all 4 authors...
Introduction: In Europe and beyond, the rising costs of healthcare and limited healthcare resources have resulted in the implementation of health technology assessment (HTA) to inform health policy and reimbursement decision-making. European legislation has harmonised the regulatory process with the European Medicines Agency now responsible for granting marketing authorisation, but reimbursement decision-making still remains the responsibility of each country. There is a recognized need to move ...
15 CitationsSource
#1Anna Mae ScottH-Index: 6
#2Bjørn Hofmann (University of Oslo)H-Index: 24
Last. Yvonne Bombard (U of T: University of Toronto)H-Index: 20
view all 6 authors...
Introduction: Assessment of ethics issues is an important part of health technology assessments (HTA). However, in terms of existence of quality assessment tools, ethics for HTA is methodologically under-developed in comparison to other areas of HTA, such as clinical or cost effectiveness.Objective: To methodologically advance ethics for HTA by: (1) proposing and elaborating Q-SEA, the first instrument for quality assessment of ethics analyses, and (2) applying Q-SEA to a sample systematic revie...
4 CitationsSource
#1Eva Rehfuess (LMU: Ludwig Maximilian University of Munich)H-Index: 29
#2Ansgar Gerhardus (University of Bremen)H-Index: 12
1 CitationsSource
#1Rob Baltussen (Radboud University Nijmegen)H-Index: 40
#2Maarten Jansen (Radboud University Nijmegen)H-Index: 5
Last. G.J. van der Wilt (Radboud University Nijmegen)H-Index: 32
view all 8 authors...
Abstract Priority setting in health care has been long recognized as an intrinsically complex and value-laden process. Yet, health technology assessment agencies (HTAs) presently employ value assessment frameworks that are ill fitted to capture the range and diversity of stakeholder values and thereby risk compromising the legitimacy of their recommendations. We propose "evidence-informed deliberative processes" as an alternative framework with the aim to enhance this legitimacy. This framework ...
28 CitationsSource
#1Eleanor M. Perfetto (UMB: University of Maryland, Baltimore)H-Index: 9
#2Em Oehrlein (UMB: University of Maryland, Baltimore)H-Index: 3
Last. Eric GaschoH-Index: 1
view all 5 authors...
Abstract Background Professional societies and other organizations have recently taken a visible role trying to define treatment value via value frameworks and assessments, providing payer or provider recommendations, and potentially impacting patient access. Patient perspectives routinely differ from those of other stakeholders. Yet, it is not always apparent that patients were engaged in value framework development or assessment. Objectives To describe the development and content of the Nation...
15 CitationsSource
The Patient-Centered Outcomes Research Institute (PCORI), created to fund research guided by patients, caregivers, and the broader health care community, offers a new research venue. Many (41 of 50) first funded projects involved qualitative research methods. This study was completed to examine the current state of the science of qualitative methodologies used in PCORI-funded research. Principal investigators participated in phenomenological interviews to learn (a) how do researchers using quali...
9 CitationsSource
Cited By5
#1Gordon G. Liu (PKU: Peking University)H-Index: 19
#2Eric Q. Wu (AG: Analysis Group)H-Index: 42
Last. Hongbo Yang (AG: Analysis Group)H-Index: 11
view all 6 authors...
Abstract Health technology assessment (HTA) has long been employed by many countries around the world, but its adoption in Asia has been slower. Only recently have a growing number of Asian countries started to implement HTA for pricing and reimbursement decisions. The objective of this article is to provide an overview of how HTA has been or is being implemented in Asia within the context of a country’s existing—and often complex—coverage, reimbursement, and pricing schemes. Three countries at ...
#1Matthew Franklin (University of Sheffield)H-Index: 14
#2James Lomas (Ebor: University of York)H-Index: 6
Last. Gerald Richardson (Ebor: University of York)H-Index: 32
view all 3 authors...
This article provides an educational review covering the consideration of conducting 'value for money' analyses as part of non-randomised study designs including service evaluations. These evaluations represent a vehicle for producing evidence such as value for money of a care intervention or service delivery model. Decision makers including charities and local and national governing bodies often rely on evidence from non-randomised data and service evaluations to inform their resource allocatio...
#1B. Desai (UMB: University of Maryland, Baltimore)
#2Todd Joseph Mattingly (UMB: University of Maryland, Baltimore)
Last. Eleanor M. Perfetto (UMB: University of Maryland, Baltimore)H-Index: 9
view all 7 authors...
Abstract Objectives Value and health technology assessment (V/HTA) is often used in clinical, access, and reimbursement decisions. V/HTA data-source selection may not be transparent, which is a necessary element for stakeholder understanding and trust and for fostering accountability among decision makers. Peer review is considered one mechanism for judging data trustworthiness. Our objective was (1) to use publicly available documentation of V/HTA methods to identify requirements for inclusion ...
#1Fokko P. Wieringa (UM: Maastricht University)H-Index: 4
#2Murray Sheldon (CDRH: Center for Devices and Radiological Health)H-Index: 2
Last. Ana Hidalgo-Simon (European Medicines Agency)H-Index: 6
view all 3 authors...
Regulations for market access and reimbursement of medical devices vary across jurisdictions, complicating the development of innovative technologies for world-wide use; however, several converging regulatory principles are now emerging. Here we discuss approaches by which regulatory and related agencies can promote innovation and boost the effectiveness of regulatory processes to expedite patient access to innovative technologies, including renal replacement therapies.
#1Christopher Carroll (University of Sheffield)H-Index: 29
#2Andrew J. Tattersall (University of Sheffield)H-Index: 15
Abstract Objectives Health technology assessment aims to inform and support healthcare decision making, and trials are part of that process. The purpose of this study was to measure the impact of a sample of trials in a meaningful but robust fashion. Methods All randomized controlled trials funded and published by the UK National Institute of Health Research in the Health Technology Assessment journal series and other peer-reviewed journals were identified for 2006 to 2015. Citation analysis was...
A key working session, held as part of the Health Technology Assessment international (HTAi) Global Policy Forum meeting asks members to share "What's Keeping Me Up At Night." Members-senior thought leaders from health technology assessment (HTA) agencies, payer organizations, industry, and the HTAi Board-share without fear or favor the thorny issues related to HTA that are challenging them now or likely to do so in the near future. This article contains a reflection on the discussions at this s...
#2Rita Karam (Lebanese University)H-Index: 2
Last. Julia ChamovaH-Index: 1
view all 13 authors...
Introduction: Implementation of health technology assessment (HTA) is still in an early stage with some heterogeneity in the Middle East and North Africa (MENA). Our objective was to assess the current and future status of HTA implementation in the MENA region by focusing on regional commonalities. Methods: Preparatory discussions for the first ISPOR conference in the MENA region indicated some potentially generalizable trends of HTA roadmaps. To widen the perspective, a policy survey was conduc...
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
#2R Thwaites (Takeda Pharmaceutical Company)H-Index: 2
Last. Jovelle Fernandez (Takeda Pharmaceutical Company)
view all 4 authors...
AbstractBackground: In Japan, pharmacoeconomic requirements for list-price adjustment were institutionalized in April 2019 following provisional implementation of a new Health Technology Assessment...
OBJECTIVES: In the last two decades, several countries in Latin America (LA) have shown an interest in developing health technology assessments (HTAs), but the process has not been uniform and has often been challenged by the health systems characteristics and the political or economic idiosyncrasies of these countries. METHODS: This article summarizes the discussions held by the participants at the 40th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) HTA Council Roundt...